Page 177 - ESHRE2019

Signs / Symptoms
Cases (n = 5540)
%
Controls (n = 21 239)
%
OR (95% CI)
Pelvic pain
862
15.6
312
1.5
13.5 (11.7–15.7)
Ovarian cysts
375
6.8
125
0.6
12.2 (9.9–15.0)
Dysmenorrhoea
1364
24.6
725
3.4
9.8 (8.8–10.9)
Dyspareunia
509
9.2
219
1
9.4 (8.0–11.1)
Ovary pain
12
0.2
5
0
9.1 (3.2–26.0)
Intermenstrual pain
74
1.3
42
0.2
6.9 (4.7–10.2)
Pelvic inflammatory disease
569
10.3
391
1.8
6.4 (5.6–7.4)
Infertility/subfertility
533
9.6
377
1.8
6.2 (5.4–7.1)
Abdominal pain (cause not specified)
2500
45.1
2739
12.9
5.9 (5.5–6.4)
Menorrhagia
1282
23.1
1269
6
5.0 (4.6–5.5)
Irritable bowel syndrome
587
10.6
702
3.3
3.5 (3.1–3.9)
Menstrual problems (other)
1492
26.9
2804
13.2
2.5 (2.3–2.7)
Dysuria
340
6.1
576
2.7
2.4 (2.1–2.7)
Dyschezia
2
0.0
3
0
2.3 (0.4–14.1)
Constipation
510
9.2
942
4.4
2.2 (2.0–2.5)
Urinary tract infection
1027
18.5
2074
9.8
2.1 (2.0–2.3)
Vaginal discharge
1756
31.7
3979
18.7
2.0 (1.9–2.2)
Rectal bleeding
111
2.0
227
1.1
1.9 (1.5–2.4)
Cystitis
485
8.8
1132
5.3
1.7 (1.5–1.9)
Ballard et al., 2008
Risk factors
• Prospective Study
• 1396 symptomatic women • 19 hospitals, 13 countries
 Menstrual dyschezia + Hx of benign ovarian cysts Any stage: AUC 68.3 Sensitivity 84.8% Specificity 43.5%
rASRM III/IV: AUC 83.3 Sensitivity 70.9% Specificity 84.7%
Nnoaham et al., 2012
172
PRECONGRESS COURSE 03 I VIENNA, AUSTRIA – 23 JUNE 2019 175